Pliant Therapeutics Inc (NAS:PLRX)

$ 15.51 1.71 (12.39%) Market Cap: 943.84 Mil Enterprise Value: 495.48 Mil PE Ratio: 0 PB Ratio: 2.73 GF Score: 41/100

Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call Transcript
Feb 05, 2024
Pliant Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 28, 2023
Pliant Therapeutics Inc INTEGRIS-PSC Interim Phase 2a Data Presentation Transcript
Sep 26, 2023
Pliant Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023
Pliant Therapeutics Inc INTEGRIS-IPF Call Transcript
May 01, 2023
Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Pliant Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Pliant Therapeutics Inc at Cowen Health Care Conference Transcript
Mar 08, 2023
Pliant Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Pliant Therapeutics Inc Review Data from the 320 mg Group of the INTEGRIS-IPF Phase 2a Trial of Bexotegrast (PLN-74809) in Patients with IPF Call Transcript
Jan 23, 2023
Pliant Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 30, 2022
Pliant Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 29, 2022
Pliant Therapeutics Inc at RBC Capital Markets Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (Virtual) Transcript
Oct 07, 2022
Pliant Therapeutics Inc to Discuss Results from INTEGRIS-IPF Call Transcript
Jul 11, 2022
Pliant Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2022
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 18, 2022
Pliant Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022

Pliant Therapeutics Inc INTEGRIS-PSC Phase 2a Trial Results Call Transcript

Feb 05, 2024 / 01:30PM GMT

Release Date Price: $15.8 (-9.20%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Pliant Therapeutics' INTEGRIS-PSC Phase 2a Trial 320 milligram. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a call.

(Operator Instructions) Please be advised that today's conference is being recorded. I would like now to turn the conference over to Christopher Keenan, Vice President of Investor Relations. Please go ahead.

Christopher Keenan

Pliant Therapeutics Inc - Vice President - Investor Relations and Corporate Communications

Thank you, Michelle, and good morning, everyone. Thank you for joining us for Pliant's presentation of top-line data from the 320 mg dose group of INTEGRIS-PSC, our Phase 2a clinical trial evaluating bexotegrast, previously known as PLN-74809 in patients with primary sclerosing cholangitis. The press release that we will be referencing today is available under the Investors and Media section of our corporate website. A replay of this event and the slides accompanying this webcast will be available in the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.